STOCK TITAN

[25-NSE] Affimed N.V. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
25-NSE
Rhea-AI Filing Summary

Nasdaq Stock Market LLC has filed Form 25 to strike Affimed N.V. (AFMD) common stock from listing and registration under Section 12(b) of the Exchange Act. The notification, signed on 2025-07-21 by a Nasdaq hearings advisor, states that the exchange believes it meets all regulatory requirements for delisting. No financial results, trading data, or rationale are provided in the filing.

The action will remove AFMD from the Nasdaq Global Market once the SEC’s 10-day period elapses, and registration under Section 12(g) will be terminated after 90 days unless the company files contrary documentation. Investors should anticipate the stock moving to an over-the-counter venue or another exchange, subject to separate listing standards.

Nasdaq Stock Market LLC ha presentato il Modulo 25 per rimuovere la quotazione e la registrazione delle azioni ordinarie di Affimed N.V. (AFMD) ai sensi della Sezione 12(b) del Exchange Act. La notifica, firmata il 21 luglio 2025 da un consulente per le audizioni Nasdaq, afferma che la borsa ritiene di soddisfare tutti i requisiti normativi per la cancellazione dalla quotazione. Nel documento non sono forniti risultati finanziari, dati di negoziazione o motivazioni.

Questa azione rimuoverà AFMD dal Nasdaq Global Market al termine del periodo di 10 giorni della SEC, e la registrazione ai sensi della Sezione 12(g) sarà terminata dopo 90 giorni, salvo che la società non presenti documentazione contraria. Gli investitori devono aspettarsi che le azioni vengano trasferite a un mercato over-the-counter o a un'altra borsa, soggetta a standard di quotazione differenti.

Nasdaq Stock Market LLC ha presentado el Formulario 25 para eliminar las acciones ordinarias de Affimed N.V. (AFMD) de la cotización y registro bajo la Sección 12(b) del Exchange Act. La notificación, firmada el 21 de julio de 2025 por un asesor de audiencias de Nasdaq, indica que la bolsa considera que cumple con todos los requisitos regulatorios para la exclusión. No se proporcionan resultados financieros, datos de negociación ni razones en la presentación.

Esta acción eliminará a AFMD del Nasdaq Global Market una vez que expire el período de 10 días de la SEC, y el registro bajo la Sección 12(g) se cancelará después de 90 días, a menos que la empresa presente documentación en contrario. Los inversores deben anticipar que las acciones se muevan a un mercado extrabursátil o a otra bolsa, sujeto a estándares de cotización diferentes.

나스닥 증권거래소 LLC는 Form 25를 제출했습니다 Affimed N.V.(AFMD) 보통주를 상장 및 등록에서 제거하기 위해 Exchange Act의 Section 12(b)에 따라 제출되었습니다. 2025년 7월 21일 나스닥 청문회 고문이 서명한 통지서에는 거래소가 상장폐지에 필요한 모든 규제 요건을 충족한다고 판단한다고 명시되어 있습니다. 서류에는 재무 결과, 거래 데이터 또는 이유가 제공되지 않았습니다.

이 조치는 SEC의 10일 기간이 만료되면 AFMD를 나스닥 글로벌 마켓에서 제외하며, 회사가 반대 서류를 제출하지 않는 한 Section 12(g)에 따른 등록은 90일 후에 종료됩니다. 투자자들은 해당 주식이 장외시장이나 다른 거래소로 이전될 가능성이 있음을 예상해야 하며, 이는 별도의 상장 기준에 따릅니다.

Nasdaq Stock Market LLC a déposé le formulaire 25 pour radier les actions ordinaires d’Affimed N.V. (AFMD) de la cotation et de l’enregistrement en vertu de la section 12(b) du Exchange Act. La notification, signée le 21 juillet 2025 par un conseiller aux auditions Nasdaq, indique que la bourse estime remplir toutes les exigences réglementaires pour la radiation. Aucun résultat financier, donnée de négociation ou justification n’est fourni dans le dossier.

Cette mesure retirera AFMD du Nasdaq Global Market à l’expiration de la période de 10 jours de la SEC, et l’enregistrement en vertu de la section 12(g) sera résilié après 90 jours, sauf si la société soumet des documents contraires. Les investisseurs doivent s’attendre à ce que l’action soit transférée vers un marché de gré à gré ou une autre bourse, soumise à des normes de cotation distinctes.

Die Nasdaq Stock Market LLC hat das Formular 25 eingereicht, um die Stammaktien von Affimed N.V. (AFMD) von der Notierung und Registrierung gemäß Abschnitt 12(b) des Exchange Act zu streichen. Die Mitteilung, die am 21.07.2025 von einem Nasdaq-Hörberater unterzeichnet wurde, besagt, dass die Börse der Ansicht ist, alle regulatorischen Anforderungen für die Delistung zu erfüllen. Im Antrag werden keine Finanzdaten, Handelsinformationen oder Gründe angegeben.

Die Maßnahme wird AFMD nach Ablauf der 10-tägigen Frist der SEC vom Nasdaq Global Market entfernen, und die Registrierung nach Abschnitt 12(g) wird nach 90 Tagen beendet, sofern das Unternehmen keine gegenteiligen Unterlagen einreicht. Anleger sollten damit rechnen, dass die Aktie an einen außerbörslichen Markt oder eine andere Börse wechselt, die eigenen Notierungsanforderungen unterliegt.

Positive
  • None.
Negative
  • Nasdaq filed Form 25 to delist AFMD common stock, removing exchange listing and SEC Section 12(b) registration, which typically reduces liquidity and investor access.

Insights

TL;DR: Nasdaq is delisting AFMD; liquidity and visibility will drop, raising risk.

The Form 25 signals a formal removal of Affimed’s common shares from Nasdaq. Delistings typically erode trading volume, widen bid-ask spreads, and restrict institutional ownership because many funds cannot hold OTC securities. While the form does not disclose why Nasdaq acted, the absence of financial or compliance details limits clarity. In my view, the event is materially negative for existing shareholders and may pressure the share price as index funds and mandate-bound investors exit positions.

Nasdaq Stock Market LLC ha presentato il Modulo 25 per rimuovere la quotazione e la registrazione delle azioni ordinarie di Affimed N.V. (AFMD) ai sensi della Sezione 12(b) del Exchange Act. La notifica, firmata il 21 luglio 2025 da un consulente per le audizioni Nasdaq, afferma che la borsa ritiene di soddisfare tutti i requisiti normativi per la cancellazione dalla quotazione. Nel documento non sono forniti risultati finanziari, dati di negoziazione o motivazioni.

Questa azione rimuoverà AFMD dal Nasdaq Global Market al termine del periodo di 10 giorni della SEC, e la registrazione ai sensi della Sezione 12(g) sarà terminata dopo 90 giorni, salvo che la società non presenti documentazione contraria. Gli investitori devono aspettarsi che le azioni vengano trasferite a un mercato over-the-counter o a un'altra borsa, soggetta a standard di quotazione differenti.

Nasdaq Stock Market LLC ha presentado el Formulario 25 para eliminar las acciones ordinarias de Affimed N.V. (AFMD) de la cotización y registro bajo la Sección 12(b) del Exchange Act. La notificación, firmada el 21 de julio de 2025 por un asesor de audiencias de Nasdaq, indica que la bolsa considera que cumple con todos los requisitos regulatorios para la exclusión. No se proporcionan resultados financieros, datos de negociación ni razones en la presentación.

Esta acción eliminará a AFMD del Nasdaq Global Market una vez que expire el período de 10 días de la SEC, y el registro bajo la Sección 12(g) se cancelará después de 90 días, a menos que la empresa presente documentación en contrario. Los inversores deben anticipar que las acciones se muevan a un mercado extrabursátil o a otra bolsa, sujeto a estándares de cotización diferentes.

나스닥 증권거래소 LLC는 Form 25를 제출했습니다 Affimed N.V.(AFMD) 보통주를 상장 및 등록에서 제거하기 위해 Exchange Act의 Section 12(b)에 따라 제출되었습니다. 2025년 7월 21일 나스닥 청문회 고문이 서명한 통지서에는 거래소가 상장폐지에 필요한 모든 규제 요건을 충족한다고 판단한다고 명시되어 있습니다. 서류에는 재무 결과, 거래 데이터 또는 이유가 제공되지 않았습니다.

이 조치는 SEC의 10일 기간이 만료되면 AFMD를 나스닥 글로벌 마켓에서 제외하며, 회사가 반대 서류를 제출하지 않는 한 Section 12(g)에 따른 등록은 90일 후에 종료됩니다. 투자자들은 해당 주식이 장외시장이나 다른 거래소로 이전될 가능성이 있음을 예상해야 하며, 이는 별도의 상장 기준에 따릅니다.

Nasdaq Stock Market LLC a déposé le formulaire 25 pour radier les actions ordinaires d’Affimed N.V. (AFMD) de la cotation et de l’enregistrement en vertu de la section 12(b) du Exchange Act. La notification, signée le 21 juillet 2025 par un conseiller aux auditions Nasdaq, indique que la bourse estime remplir toutes les exigences réglementaires pour la radiation. Aucun résultat financier, donnée de négociation ou justification n’est fourni dans le dossier.

Cette mesure retirera AFMD du Nasdaq Global Market à l’expiration de la période de 10 jours de la SEC, et l’enregistrement en vertu de la section 12(g) sera résilié après 90 jours, sauf si la société soumet des documents contraires. Les investisseurs doivent s’attendre à ce que l’action soit transférée vers un marché de gré à gré ou une autre bourse, soumise à des normes de cotation distinctes.

Die Nasdaq Stock Market LLC hat das Formular 25 eingereicht, um die Stammaktien von Affimed N.V. (AFMD) von der Notierung und Registrierung gemäß Abschnitt 12(b) des Exchange Act zu streichen. Die Mitteilung, die am 21.07.2025 von einem Nasdaq-Hörberater unterzeichnet wurde, besagt, dass die Börse der Ansicht ist, alle regulatorischen Anforderungen für die Delistung zu erfüllen. Im Antrag werden keine Finanzdaten, Handelsinformationen oder Gründe angegeben.

Die Maßnahme wird AFMD nach Ablauf der 10-tägigen Frist der SEC vom Nasdaq Global Market entfernen, und die Registrierung nach Abschnitt 12(g) wird nach 90 Tagen beendet, sofern das Unternehmen keine gegenteiligen Unterlagen einreicht. Anleger sollten damit rechnen, dass die Aktie an einen außerbörslichen Markt oder eine andere Börse wechselt, die eigenen Notierungsanforderungen unterliegt.

UNITED STATES
OMB APPROVAL
OMB Number: 3235-0080
Expires: March 31, 2018
Estimated average burden
hours per response: 1.7
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 25
NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number 001-36619
Issuer: Affimed N.V.
Exchange: Nasdaq Stock Market LLC
(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
Address: Gottlieb-Daimler Strasse 2
Mannheim GERMANY 68165
Telephone number: +49-6221-65307-64
(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
Common Stock
(Description of class of securities)
Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
17 CFR 240.12d2-2(a)(1)
17 CFR 240.12d2-2(a)(2)
17 CFR 240.12d2-2(a)(3)
17 CFR 240.12d2-2(a)(4)
Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
2025-07-21 By Aravind Menon Hearings Advisor
Date Name Title
1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Why is Affimed (AFMD) being delisted from Nasdaq?

The Form 25 only states that Nasdaq has met the regulatory requirements for removal; it does not specify the underlying cause.

When will the AFMD delisting become effective?

Ten days after the Form 25 filing (2025-07-21), unless the SEC delays the process.

Will AFMD shares continue to trade after delisting?

Shares usually migrate to an over-the-counter market, but this filing does not confirm the post-delisting venue.

Does the Form 25 terminate all SEC registration for AFMD?

Section 12(g) registration ends 90 days after filing unless the company files to maintain it.

What impact does delisting have on shareholder liquidity?

Delisting generally lowers trading volume and may widen spreads, making it harder to buy or sell shares efficiently.
Affimed

NASDAQ:AFMD

AFMD Rankings

AFMD Latest News

AFMD Stock Data

2.13M
15.48M
6.01%
23.83%
4.32%
Biotechnology
Healthcare
Link
Germany
Mannheim